Cytochrome P450-mediated cardiovascular drug interactions

Bibliography

• Opie LH. Interactions with cardiovascular drugs. Curr Probl Cardiol 1993;7(9):531-81
   Google Scholar
• Opie LH. Adverse cardiovascular drug interactions. Curr Probl Cardiol 2000;25(9):621-76
   PubMedGoogle Scholar
• Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin 2001;19(2):215-34. v
   PubMedGoogle Scholar
• Page RL II, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005;111(2):230-9
   PubMed Web of Science ®Google Scholar
• Prybys KM. Deadly drug interactions in emergency medicine. Emerg Med Clin North Am 2004;22(4):845-63
   PubMed Web of Science ®Google Scholar
• Cheng JW, Frishman WH, Aronow WS. Updates on cytochrome P450-mediated cardiovascular drug interactions. Am J Ther 2009;16(2):155-63
   PubMed Web of Science ®Google Scholar
• Brown CS, Farmer RG, Soberman JE, Eichner SF. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004;43(1):33-56
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76(3):391-6
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35(5):361-90
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29(6):687-710
   PubMed Web of Science ®Google Scholar
• van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23
   PubMed Web of Science ®Google Scholar
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38(1):41-57
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44(3):279-304
   PubMed Web of Science ®Google Scholar
• Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9(4):310-22
   PubMed Web of Science ®Google Scholar
• Polasek TM, Lin FP, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 2011;71(5):727-36
   PubMed Web of Science ®Google Scholar
• Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des 2008;14(17):1723-42
   PubMed Web of Science ®Google Scholar
• Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69(13):1777-98
   PubMed Web of Science ®Google Scholar
• Lim GE, Li T, Buttar HS. Interactions of grapefruit juice and cardiovascular medications: a potential risk of toxicity. Exp Clin Cardiol 2003;8(2):99-107
   PubMedGoogle Scholar
• Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4(5):281-97
   PubMedGoogle Scholar
• Magnani B, Malini PL. Cardiac glycosides. Drug interactions of clinical significance. Drug Saf 1995;12(2):97-109
   PubMed Web of Science ®Google Scholar
• Lee CA, Cook JA, Reyner EL, Smith DA. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 2010;6(5):603-19
   PubMed Web of Science ®Google Scholar
• Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44(12):1227-46
   PubMed Web of Science ®Google Scholar
• Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121(9):676-83
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Pereira JA, Labiris R, Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095-106
   PubMed Web of Science ®Google Scholar
• Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30(6):416-44
   PubMed Web of Science ®Google Scholar
• Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004;24(2):285-90
   PubMed Web of Science ®Google Scholar
• Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003;3(3):221-30
   PubMedGoogle Scholar
• Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005;94(3):537-43
   PubMed Web of Science ®Google Scholar
• Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009;41(8):619-28
   PubMed Web of Science ®Google Scholar
• Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40(8):587-603
   PubMed Web of Science ®Google Scholar
• Kerr HD. Case report: potentiation of warfarin by fluconazole. Am J Med Sci 1993;305(3):164-5
   PubMed Web of Science ®Google Scholar
• Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. BMJ 1990;301(6753):669
   PubMed Web of Science ®Google Scholar
• Smith AG. Potentiation of oral anticoagulants by ketoconazole. Br Med J (Clin Res Ed) 1984;288(6412):188-9
   PubMed Web of Science ®Google Scholar
• Bachmann K, Schwartz JI, Forney R Jr, The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984;28(3):171-6
   PubMed Web of Science ®Google Scholar
• Recker MW, Kier KL. Potential interaction between clarithromycin and warfarin. Ann Pharmacother 1997;31(9):996-8
   PubMed Web of Science ®Google Scholar
• Rao KB, Pallaki M, Tolbert SR, Hornick TR. Enhanced hypoprothrombinemia with warfarin due to azithromycin. Ann Pharmacother 2004;38(6):982-5
   PubMed Web of Science ®Google Scholar
• Carroll DN, Carroll DG. Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother 2008;42(5):680-5
   PubMed Web of Science ®Google Scholar
• Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010;49(8):509-33
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhou S, Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab 2005;6(5):399-411
   PubMed Web of Science ®Google Scholar
• Uno T, Sugimoto K, Sugawara K, Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 2008;30(3):276-81
   PubMed Web of Science ®Google Scholar
• Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008;100(6):1052-7
   PubMed Web of Science ®Google Scholar
• Muszkat M, Blotnik S, Elami A, Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther 2007;29(3):427-37
   PubMed Web of Science ®Google Scholar
• Heimark LD, Wienkers L, Kunze K, The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51(4):398-407
   PubMed Web of Science ®Google Scholar
• Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. Ann Pharmacother 2009;43(2):322-8
   PubMed Web of Science ®Google Scholar
• Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy 2008;28(7):945-9
   PubMed Web of Science ®Google Scholar
• Rulcova A, Prokopova I, Krausova L, Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes. J Thromb Haemost 2010;8(12):2708-17
   PubMed Web of Science ®Google Scholar
• Lee CJ, Badhwar G, Ansell JE. Oral IIa inhibitors. Hematol Oncol Clin North Am 2010;24(4):739-53. ix
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang D, Raghavan N, In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010;38(3):448-58
   PubMed Web of Science ®Google Scholar
• Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64(7):956-67
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Coughtrie MW, MacDonald TM, Wei L. Antiplatelet drug interactions. J Intern Med 2010;268(6):516-29
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50(2):126-42
   PubMed Web of Science ®Google Scholar
• Ma TK, Lam YY, Tan VP, Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther 2010;125(2):249-59
   PubMed Web of Science ®Google Scholar
• Laizure SC, Parker RB. A comparison of the metabolism of clopidogrel and prasugrel. Expert Opin Drug Metab Toxicol 2010;6(11):1417-24
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010;49(12):777-98
   PubMed Web of Science ®Google Scholar
• Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome p450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 2011;39(4):703-10
   PubMed Web of Science ®Google Scholar
• Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharm Res 2006;23(12):2691-708
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Silvain J, Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010;56(2):134-43
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38(1):92-9
   PubMed Web of Science ®Google Scholar
• Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011;57(11):1251-63
   PubMed Web of Science ®Google Scholar
• Gaglia MA Jr, Waksman R. Proton pump inhibitors and clopidogrel. Cardiovasc Ther 2010;28(3):169-76
   PubMed Web of Science ®Google Scholar
• Liu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors. Pharmacotherapy 2010;30(3):275-89
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr, Dehmer GJ, Kaul S, ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010;122(5):537-57
   PubMed Web of Science ®Google Scholar
• Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010;105(1):34-41
   PubMed Web of Science ®Google Scholar
• Giorgi MA, Di Girolamo G, Gonzalez CD. Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin Pharmacother 2010;11(14):2391-403
   PubMed Web of Science ®Google Scholar
• Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009;43(7):1266-74
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52(19):1557-63
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96(3):186-9
   PubMed Web of Science ®Google Scholar
• Harmsze AM, Robijns K, van Werkum JW, The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010;103(5):920-5
   PubMed Web of Science ®Google Scholar
• Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opin Pharmacother 2011;12(8):1285-95
   PubMed Web of Science ®Google Scholar
• Ha HR, Follath F. Metabolism of antiarrhythmics. Curr Drug Metab 2004;5(6):543-71
   PubMed Web of Science ®Google Scholar
• Trujillo TC, Nolan PE. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000;23(6):509-32
   PubMed Web of Science ®Google Scholar
• Galetin A, Ito K, Hallifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005;314(1):180-90
   PubMed Web of Science ®Google Scholar
• Baciewicz AM, Baciewicz FA Jr. Effect of cimetidine and ranitidine on cardiovascular drugs. Am Heart J 1989;118(1):144-54
   PubMed Web of Science ®Google Scholar
• Lim KS, Cho JY, Jang IJ, Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 2008;66(5):660-6
   PubMed Web of Science ®Google Scholar
• Lim KS, Jang IJ, Kim BH, Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects. Clin Ther 2010;32(4):659-66
   PubMed Web of Science ®Google Scholar
• Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26(6):421-38
   PubMed Web of Science ®Google Scholar
• Lai XS, Yang LP, Li XT, Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 2009;10(9):1009-47
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Suzuki M, Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000;49(3):244-53
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Kobayashi T, Tachibana K, Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet 2006;21(6):501-5
   PubMed Web of Science ®Google Scholar
• Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010;15(4 Suppl):15S-18S
   PubMed Web of Science ®Google Scholar
• Damy T, Pousset F, Caplain H, Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004;18(1):113-23
   PubMed Web of Science ®Google Scholar
• Wehling M. Multimorbidity and polypharmacy: which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung 2010;60(2):57-63
   PubMed Web of Science ®Google Scholar
• Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung 2003;53(12):814-22
   PubMed Web of Science ®Google Scholar
• Lindamood C, Ortiz S, Shaw A, Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol 2011;51(4):575-85
   PubMed Web of Science ®Google Scholar
• Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens (Greenwich) 2005;7(4 Suppl 1):21-6
   PubMedGoogle Scholar
• Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, Dayer P. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 1999;55(8):559-65
   PubMed Web of Science ®Google Scholar
• Welker HA, Wiltshire H, Bullingham R. Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 1998;35(6):405-23
   PubMed Web of Science ®Google Scholar
• Katoh M, Nakajima M, Shimada N, Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000;55(11-12):843-52
   PubMed Web of Science ®Google Scholar
• Nishio S, Watanabe H, Kosuge K, Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005;28(3):223-7
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Aberg JA, Kendall MA, Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005;78(2):143-53
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32(2):259-66
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 2010;49(4):239-58
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64(2):177-82
   PubMed Web of Science ®Google Scholar
• Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001;51(5):461-70
   PubMed Web of Science ®Google Scholar
• Maggio TG, Bartels DW. Increased cyclosporine blood concentrations due to verapamil administration. Drug Intell Clin Pharm 1988;22(9):705-7
   PubMedGoogle Scholar
• Edwards DJ, Lavoie R, Beckman H, The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. Clin Pharmacol Ther 1987;41(1):68-73
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 2005;33(5):664-71
   PubMed Web of Science ®Google Scholar
• Reed M, Wall GC, Shah NP, Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother 2005;39(2):357-60
   PubMed Web of Science ®Google Scholar
• Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24(4):796-801
   PubMed Web of Science ®Google Scholar
• Choi DH, Chung JH, Choi JS. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Eur J Clin Pharmacol 2010;66(3):285-90
   PubMed Web of Science ®Google Scholar
• Choi DH, Shin WG, Choi JS. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol 2008;64(5):445-9
   PubMed Web of Science ®Google Scholar
• Srinivas NR. Dual drug interactions via P-glycoprotein (P-gp)/cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil. Eur J Clin Pharmacol 2008;64(11):1135-6
   PubMed Web of Science ®Google Scholar
• Azie NE, Brater DC, Becker PA, The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64(4):369-77
   PubMed Web of Science ®Google Scholar
• Masica AL, Azie NE, Brater DC, Intravenous diltiazem and CYP3A-mediated metabolism. Br J Clin Pharmacol 2000;50(3):273-6
   PubMed Web of Science ®Google Scholar
• Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000;67(3):267-74
   PubMed Web of Science ®Google Scholar
• Kanathur N, Mathai MG, Byrd RP Jr, Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001;94(9):339-41
   PubMedGoogle Scholar
• Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998;18(2):381-5
   PubMed Web of Science ®Google Scholar
• Khoury V, Kritharides L. Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension. Aust NZ J Med 2000;30(5):641-2
   PubMedGoogle Scholar
• Maas R, Boger RH. Antihypertensive therapy: special focus on drug interactions. Expert Opin Drug Saf 2003;2(6):549-79
   PubMedGoogle Scholar
• Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002;162(4):405-12
   PubMed Web of Science ®Google Scholar
• Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993;25(1):20-58
   PubMed Web of Science ®Google Scholar
• Bohler S, Pittrow D, Bramlage P, Kirch W. Drug interactions with angiotensin receptor blockers. Expert Opin Drug Saf 2005;4(1):7-18
   PubMedGoogle Scholar
• Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin Pharmacokinet 2001;40(8):605-14
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jarugula V, Dieterich HA, Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47(8):515-31
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Camenisch G, Schuetz H, Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008;48(11):1323-38
   PubMed Web of Science ®Google Scholar
• Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005;28(3):263-75
   PubMed Web of Science ®Google Scholar
• Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32(5):403-25
   PubMed Web of Science ®Google Scholar
• Rowan C, Brinker AD, Nourjah P, Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009;18(4):301-9
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94(9):1140-6
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112(1):71-105
   PubMed Web of Science ®Google Scholar
• Frishman WH, Horn J. Statin-drug interactions: not a class effect. Cardiol Rev 2008;16(4):205-12
   PubMed Web of Science ®Google Scholar
• Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41(5):343-70
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008;47(7):463-74
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10(1):11-28
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80(6):565-81
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010;11(3):323-32
   PubMed Web of Science ®Google Scholar
• Asberg A. Interactions between cyclosporine and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003;63(4):367-78
   PubMed Web of Science ®Google Scholar
• Tafreshi MJ, Zagnoni LG, Gentry EJ. Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma? Pharmacotherapy 2006;26(3):388-94
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Windecker S, Billinger M, Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol 2007;99(3):353-6
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Eshtehardi P, Abrecht L, A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Thromb Haemost 2010;104(3):554-62
   PubMed Web of Science ®Google Scholar
• Geisler T, Zurn C, Paterok M, Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008;29(13):1635-43
   PubMed Web of Science ®Google Scholar
• Blagojevic A, Delaney JA, Levesque LE, Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiol Drug Saf 2009;18(5):362-9
   PubMed Web of Science ®Google Scholar
• Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Des 2006;12(10):1271-80
   PubMed Web of Science ®Google Scholar
• Bhindi R, Ormerod O, Newton J, Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 2008;101(12):915-25
   PubMed Web of Science ®Google Scholar
• Lozada A, Dujovne CA. Drug interactions with fibric acids. Pharmacol Ther 1994;63(2):163-76
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Richards KM, Qiu Y, Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 2005;22(1):71-8
   PubMed Web of Science ®Google Scholar
• Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34(2):155-62
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30(11):1280-7
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Murphy G, Burke J, Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44(9):1054-62
   PubMed Web of Science ®Google Scholar
• Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006;5(1):145-56
   PubMed Web of Science ®Google Scholar
• Kim KY, Mancano MA. Fenofibrate potentiates warfarin effects. Ann Pharmacother 2003;37(2):212-15
   PubMed Web of Science ®Google Scholar
• Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 2009;29(6):744-8
   PubMed Web of Science ®Google Scholar
• Wen X, Wang JS, Backman JT, Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001;29(11):1359-61
   PubMed Web of Science ®Google Scholar
• Backman JT, Honkalammi J, Neuvonen M, CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos 2009;37(12):2359-66
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34(1):191-7
   PubMed Web of Science ®Google Scholar
• Wang JS, Neuvonen M, Wen X, Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002;30(12):1352-6
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311(1):228-36
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46(3):347-51
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 2005;97(4):249-56
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Juntti-Patinen L, Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 2005;60(2):208-17
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Granfors M, Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003;46(10):1319-23
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009;15(27):3179-92
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Saf 1995;12(1):32-45
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005;28(7):601-31
   PubMed Web of Science ®Google Scholar
• Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009;5(3):225-41
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30(5):359-71
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46(2):93-108
   PubMed Web of Science ®Google Scholar
• Kaul S, Bolger AF, Herrington D, Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010;121(16):1868-77
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007;46(1):1-12
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 2009;18(10):1495-503
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49(9):573-88
   PubMed Web of Science ®Google Scholar
• Dhillon S, Weber J. Saxagliptin. Drugs 2009;69(15):2103-14
   PubMed Web of Science ®Google Scholar